IP Library Granted Patent US 11,998,479
Granted Patent B2
US 11,998,479 · App. 18/234,544 · Granted Jun 4, 2024

Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure

Inventors: Sheri Simmons (Brookline, MA); Tye Jensen (Telluride, CO); Joseph E. Kovarik (Englewood, CO)
Assignee: Seed Health, Inc.
A61F5/566
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,998,479
App. No.
18/234,544
Granted
Jun 4, 2024
Kind
B2
Abstract

A method and system to address the adverse effects on an individual's oral microbiome with the objective of restoring gingival health caused by exposure to sodium lauryl sulfate. Certain embodiments of the present invention facilitate the growth of desired bacteria in a human's mouth to reduce the likelihood of dental caries, halitosis, canker sores, and other oral diseases. Probiotic bacterial, bioactive flavonoid, xylitol and zinc compound compositions, provide effective prevention and treatment options, especially while precluding the use of sodium lauryl sulfate so as to reduce adverse consequences it has on gingival health.

Claims (41)

1. A method for reducing the likelihood of developing dental caries and halitosis, comprising:

providing to an oral cavity of an individual subject:

a first bacterial composition comprising beneficial bacteria adapted to form a biofilm, said beneficial bacteria comprising a bacterium of the genus Rothia;

a second composition comprising:

an oral probiotic comprising at least two of the following bacteria: Lactobacillus brevis CD2, Streptococcus sanguinis BCC23, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus johnsonii, Bifidobacterium bifidum, Enterococcus faecium, Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lachnospira, Veillonella, Faecalibacterium and Prevotella;

at least one zinc-based compound selected from the group consisting of zinc acetate, zinc chloride, zinc citrate, and zinc sulphate; and

at least one bioactive flavonoid selected from the group consisting of baicalein, naringenin, catechins, quercetin, trans-resveratrol, luteolin, kaempferol, hesperidin, hesperetin, naringin, diosmin, rutin, nobiletin, and tangeretin; and

wherein the oral probiotic lowers the pH of the individual subject's oral cavity in an amount sufficient to disrupt the formation of biofilms by pathogenic bacteria.

2. The method of claim 1 , wherein the step of providing comprises topically administering said second composition in the form of one of a toothpaste, mouth wash, chewing gum, oral strip, extruded chew and jerky chew.

3. The method of claim 1 , further comprising, using a clustered regularly interspaced short palindromic repeats (CRIPSR)-CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Franscisella 1 (Cpf1a) system, selectively killing pathogenic bacteria in the individual subject's oral cavity.

4. The method of claim 1 , wherein said step of providing the first bacterial composition is performed after the individual subject has cleaned their teeth with a toothpaste devoid of sodium lauryl sulphate (SLS).

5. The method of claim 1 , wherein said second composition comprises Veillonella bacteria.

6. The method of claim 1 , wherein said second composition further comprises breath freshening components.

7. The method as set forth in claim 1 , further comprising providing at least one bacteria that has been modified by employment of a CRISPR-Cas or Cpf1 system to remove a virulence factor selected from the group consisting of gelatinase and hemolysin.

8. The method as set forth in claim 1 , wherein the individual subject is a human.

9. The method as set forth in claim 1 , wherein the individual subject is a canine.

10. The method as set forth in claim 1 , wherein the first bacterial composition and the second are combined.

11. A method for reducing the likelihood of developing dental caries and halitosis, comprising:

providing to an oral cavity of an individual subject:

a first bacterial composition comprising beneficial bacteria adapted to form a biofilm, said beneficial bacteria comprising a bacterium of the genus Rothia , and wherein said bacterial composition does not inhibit growth of a bacterium of species Lactobacillus salivarius ; said step of providing performed after the individual subject has cleaned their teeth with a toothpaste devoid of sodium lauryl sulphate (SLS);

a second composition comprising:

an oral probiotic comprising at least two of the following bacteria: Lactobacillus brevis CD2, Streptococcus sanguinis BCC23, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus johnsonii, Bifidobacterium bifidum, Enterococcus faecium, Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lachnospira, Veillonella, Faecalibacterium and Prevotella;

at least one zinc-based compound selected from the group consisting of zinc acetate, zinc chloride, zinc citrate, and zinc sulphate; and

at least one bioactive flavonoid selected from the group consisting of baicalein, naringenin, catechins, quercetin, trans-resveratrol, Luteolin, kaempferol, hesperidin, hesperetin, naringin, diosmin, rutin, nobiletin, and tangeretin; and

wherein the halitosis is caused by a pathogenic bacteria that generates volatile sulfur compounds comprising one of methylmercaptan and hydrogen sulfite.

12. The method as set forth in claim 11 , further comprising using a clustered regularly interspaced short palindromic repeats (CRIPSR)-CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Franscisella 1 (Cpf1a) system, selectively killing pathogenic bacteria in the individual subject's oral cavity.

13. The method as set forth in claim 11 , wherein said pathogenic bacteria is Porphyromonas gingivalis.

14. The method as set forth in claim 11 , wherein the individual subject is a human.

15. The method as set forth in claim 14 , wherein the individual subject is a canine.

16. A method for reducing the likelihood of developing dental caries and halitosis, comprising:

providing to an oral cavity of an individual subject:

a first bacterial composition comprising beneficial bacteria adapted to form a biofilm, said beneficial bacteria comprising a bacterium of the genus Rothia , and wherein said bacterial composition does not inhibit growth of a bacterium of species Lactobacillus salivarius ; said step of providing performed after the individual subject has cleaned their teeth;

a second composition comprising:

an oral probiotic comprising at least two of the following bacteria: Lactobacillus brevis CD2, Streptococcus sanguinis BCC23, Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus casei strain Shirota, and Veillonella;

at least one zinc-based compound selected from the group consisting of zinc acetate, zinc chloride, zinc citrate, and zinc sulphate; and

at least one bioactive flavonoid selected from the group consisting of quercetin, nobiletin, tangeretin; and xylitol; and

wherein said step of providing the first bacterial composition is performed after the individual subject has cleaned their teeth with a toothpaste devoid of sodium lauryl sulphate (SLS).

17. The method of claim 1 , wherein said second composition is in the form of one of a toothpaste, mouth wash, gargle solution, nose spray, mouth spray, throat spray, chewing gum, hydrogel, oral strip, and oral cream.

18. The method of claim 1 , wherein said oral probiotic comprises Lactobacillus casei , strain Shirota.

19. The method as set forth in claim 16 , further comprising providing at least one bacteria that has been modified by employment of a CRISPR-Cas or Cpf1 system to remove a virulence factor selected from the group consisting of gelatinase and hemolysin.

20. The method of claim 16 , further comprising, using a clustered regularly interspaced short palindromic repeats (CRIPSR)-CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Franscisella 1 (Cpf1a) system, selectively killing pathogenic bacteria in the individual subject's oral cavity.

Assignments (2)
SECURITY INTEREST Recorded Jul 21, 2026
From: SEED HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A., AS LENDER
Reel/Frame 076028/0339 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2023
From: SIMMONS, SHERI; JENSEN, TYE; KOVARIK, JOSEPH E.
To: SEED HEALTH, INC.
Reel/Frame 065207/0813 →
Continuity (29)
Continuation In Part 18103768 · Jan 31, 2023
Continuation In Part 17738771 · May 6, 2022
Continuation In Part 16904056 · Jun 17, 2020
Continuation In Part 15983250 · May 18, 2018
Continuation In Part 15384716 · Dec 20, 2016
Continuation In Part 15270034 · Sep 20, 2016
Continuation In Part 15228454 · Aug 4, 2016
Continuation 14954074 · Nov 30, 2015
Continuation In Part 14752192 · Jun 26, 2015
Continuation In Part 14611458 · Feb 2, 2015
Continuation In Part 14574517 · Dec 18, 2014
Continuation 14502097 · Sep 30, 2014
Continuation 14307651 · Jun 18, 2014
Continuation In Part 14225503 · Mar 26, 2014
Continuation In Part 14079054 · Nov 13, 2013
Continuation 13425913 · Mar 21, 2012
Continuation 13367052 · Feb 6, 2012
Provisional Application 62275341 · Jan 6, 2016
Provisional Application 62274550 · Jan 4, 2016
Provisional Application 62387404 · Dec 24, 2015
Provisional Application 62387405 · Dec 24, 2015
Provisional Application 62072476 · Oct 30, 2014
Provisional Application 62053926 · Sep 23, 2014
Provisional Application 62014855 · Jun 20, 2014
Provisional Application 61919297 · Dec 20, 2013
Provisional Application 61556023 · Nov 4, 2011
Provisional Application 61467767 · Mar 25, 2011
Provisional Application 61439652 · Feb 4, 2011
Related Publication 20240024154A1 · Jan 25, 2024
Cited By (7)
US 12,257,272 US 12,279,989 US 12,318,411 US 12,318,414 US 12,329,783 US 12,357,662 US 12,533,312